Outcome

Outcome Capital Promotes Thomas Busby to Director to Expand Medical Device and Life Science Services Practices

Retrieved on: 
Thursday, January 11, 2024
Professional Services, Health, Medical Devices, Health Technology, Other Science, Finance, Science, Capital, MBA, Outcome, Suffolk University, Entrepreneurship

Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Thomas F. Busby has been promoted to Director at Outcome’s Boston office.

Key Points: 
  • Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Thomas F. Busby has been promoted to Director at Outcome’s Boston office.
  • Mr. Busby, formerly Senior Vice President at Outcome, will focus on the medical device, digital health and life science services verticals within Outcome’s unique strategy-driven platform, providing M&A, capital raising and advisory services to his clients.
  • Mr. Busby joined Outcome Capital in 2015 and has advised dozens of management teams throughout the life sciences spectrum.
  • It has been my pleasure to grow alongside Outcome Capital, and in this new role I look forward to continuing this trajectory,” commented Mr. Busby.

Outcome Capital Announces Acquisition of Propella Therapeutics, Portfolio Company of Peterson Companies, by Astellas Pharma

Retrieved on: 
Thursday, January 4, 2024
Professional Services, Health, Finance, Banking, Pharmaceutical, Biotechnology, CYP17, Acquisition, Tissue, Prostate cancer, Therapy, Patient, Outcome, Safety, Capital, Pharmaceutical industry

Outcome Capital is a strategic advisor to Peterson Companies, majority shareholder of Propella.

Key Points: 
  • Outcome Capital is a strategic advisor to Peterson Companies, majority shareholder of Propella.
  • Astellas and Propella have entered into a merger agreement pursuant to which Astellas will acquire Propella.
  • Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform enabling lymphatic targeting of novel oncology drugs.
  • Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.

The Rise Fund to Make Majority Investment in Outcomes First Group Joined by Investcorp

Retrieved on: 
Tuesday, December 12, 2023
Banking, Mental Health, Fund Raising, General Health, Professional Services, Foundation, Philanthropy, People with Disabilities, Consumer, Clinical Trials, Health, Other Philanthropy, Other Education, Continuing, Education, Socially Responsible Investing, Finance, Funding, Ropes & Gray, SEN, Moelis & Company, DLA Piper, OFG, Investment, Stirling Square Capital Partners, Piper, Student, FirstGroup, Learning, Rise, Neuro, Venture capital financing, Stirling Square, Special, Occupational therapy, Private equity, Partnership, Ofsted, Growth, Mental health, Gibson Dunn, Parent, Spectrum, The Rise, Mental, Outcomes First Group, Nursing, Renewable energy, Outcome, Employment, Investcorp

The Rise Fund is making a majority investment in OFG with Investcorp making a minority investment.

Key Points: 
  • The Rise Fund is making a majority investment in OFG with Investcorp making a minority investment.
  • “This is the start of an exciting new chapter for Outcomes First Group,” said David Leatherbarrow, CEO of Outcomes First Group.
  • Moelis & Company served as financial advisor to The Rise Fund and Investcorp in relation to the transaction.
  • Ropes & Gray and Gibson, Dunn & Crutcher served as legal counsel to The Rise Fund and Investcorp respectively.

Itron Joins the Green Button Alliance to Help Advance Green Button Standard

Retrieved on: 
Wednesday, November 15, 2023
Software, Networks, Internet, Utilities, Other Natural Resources, Data Management, Alternative Energy, Energy, Technology, Natural Resources, Environment, Green Technology, GBA, ITRI, Outcome, Intelligence, City, Sim Van der Ryn, Water, Green, Renewable energy, Itron

The Green Button Connect My Data® and Green Button Download My Data® standards enable energy and water users to digitally access their usage data, manage energy consumption more efficiently and conserve resources, while ensuring customer data privacy.

Key Points: 
  • The Green Button Connect My Data® and Green Button Download My Data® standards enable energy and water users to digitally access their usage data, manage energy consumption more efficiently and conserve resources, while ensuring customer data privacy.
  • Joining the GBA as a Participating Member aligns Itron with other forward looking industry leaders and innovators to further the proliferation of standards-based Green Button solutions.
  • Aligning these solutions with the Green Button standard is critical to ensure all parties have secure access to data needed for a distributed energy future.
  • “As we work to advance the Green Button standard, and customers increasingly look to innovative Green Button data-enabled solutions to view and manage resources, we welcome Itron—and the broad market knowledge its team brings—to the Green Button Alliance.”

Curavit Launches Health Economics and Outcomes Research (HEOR) Practice for Pharmaceutical Clinical Trials; Increasingly Critical for Digital Therapeutics

Retrieved on: 
Tuesday, October 31, 2023
Digital, Research, Insurance, Therapy, Government, Orchestra, Mortality, Conditional sentence, DTA, Geography, Environment, DCTS, Clinical trial, Walking, Single-frequency network, Language, Patient, Outcome, Pharmaceutical industry, Nursing, Stroke

NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), launches new Health Economics and Outcomes Research (HEOR) Practice.  Curavit will incorporate HEOR services in clinical trials to capture evidence of the health economics value of novel pharmaceutical products, especially digital therapeutics which are striving to accelerate market momentum. Curavit will assess the value and effect of DTx interventions on both individual patients and population health levels of care.

Key Points: 
  • NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Curavit Clinical Research , a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), launches new Health Economics and Outcomes Research (HEOR) Practice.
  • Curavit will incorporate HEOR services in clinical trials to capture evidence of the health economics value of novel pharmaceutical products, especially digital therapeutics which are striving to accelerate market momentum.
  • Curavit will assess the value and effect of DTx interventions on both individual patients and population health levels of care.
  • Curavit and the Digital Therapeutics Alliance will be co-hosting educational events on November 3 in Boston, and December 7 in San Francisco.

Itron’s Advanced Settlement Module Provides High Granularity, Industry-Leading Integration and Complete Energy Market Coverage

Retrieved on: 
Wednesday, October 25, 2023
Software, Other Energy, Hardware, Utilities, Other Natural Resources, Alternative Energy, Energy, Technology, Natural Resources, Environment, Green Technology, Other Technology, Ageing, Water, Federal Energy Regulatory Commission, Data collection, Power, Wind, Organization, Electricity, Data management, DER, VPP, City, Bundesverband der Energie- und Wasserwirtschaft, IEE, Settlement, Virtual power plant, ITRI, Outcome, Renewable energy, Itron

From five-minute settlements to integrating the newest entrants into the energy market, such as wind, solar, batteries and Virtual Power Plants (VPPs), IEE Settlements sets a new standard for granularity in energy market coverage and reporting.

Key Points: 
  • From five-minute settlements to integrating the newest entrants into the energy market, such as wind, solar, batteries and Virtual Power Plants (VPPs), IEE Settlements sets a new standard for granularity in energy market coverage and reporting.
  • Energy settlements – the process of capturing and reconciling energy generation and consumption, both at the wholesale and retail levels – play a crucial role in the energy market where energy is traded.
  • As this market evolves, it is essential to quantify energy generation and consumption within specific intervals and reconcile disparities between the energy generated and the energy consumed.
  • “The newly launched IEE Settlements module addresses crucial challenges facing aging infrastructure and the utility settlement market.

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

Retrieved on: 
Sunday, October 15, 2023
Technology, Surgery, Managed Care, Medical Devices, General Health, Hospitals, Clinical Trials, Cardiology, Wearables, Mobile Technology, Health, Health Technology, Other Technology, Telemedicine, Virtual Medicine, Software, Biometrics, Other Health, Practice Management, Annual general meeting, Abstract, Caregiver, Outcome, Mortality, Vital signs, Principal, Workforce, COSMOS, Fatigue, Research, GE, ASA, Respiratory rate, Burnout, GE HealthCare, Patient, Cleveland Clinic, Medical device, Pharmaceutical industry, Nursing, MD

GE HealthCare (Nasdaq: GEHC) today announced new data from a pilot study conducted with Cleveland Clinic evaluating the Portrait Mobile wireless and wearable monitoring solution.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) today announced new data from a pilot study conducted with Cleveland Clinic evaluating the Portrait Mobile wireless and wearable monitoring solution.
  • The results demonstrate that continuous patient monitoring with Portrait Mobile resulted in alarm data suitable for optimization of ward default values and further refinement on an individual basis seems likely to improve usability.
  • The COSMOS (Continuous Ward Monitoring with the GE HealthCare Portrait Mobile Monitoring Solution) Phase 1 study enrolled 100 post-surgical patients who had respiratory rate, oxygen saturation, and pulse rate monitored continuously with Portrait Mobile.
  • While only representing 6% of all patients, the patients with >24 alarms per day accounted for 46% (n=617) of total alarms.

HEALTHSCOPE : AI ENABLES PATIENT EMOTIONS TO BE ANALYSED IMPROVING HOSPITAL EXPERIENCE.

Retrieved on: 
Sunday, October 15, 2023
Food, Perception, Hospital, ICC, Emotion, AI, Anger, Queen's University, Heart, Procter & Gamble, University, Artificial intelligence, Trust, Experience, Rock and Blues Custom Show, Patient, Allstate, Comment, Nursing, Medical device, Retail, Amazon, Outcome, Healthscope

Anita Hodge National Manager Reported Experience and Outcomes for Healthscope says going beyond numbers to "understand patient emotions and each individual story" now plays a key role to better understanding how to improve patient experience.

Key Points: 
  • Anita Hodge National Manager Reported Experience and Outcomes for Healthscope says going beyond numbers to "understand patient emotions and each individual story" now plays a key role to better understanding how to improve patient experience.
  • Patient experience includes everything from admissions processes, to the food patients eat, to the bedside manner of clinicians to patients being discharged.
  • By improving factors such as these, evidence from clinical studies have shown this leads to better patient outcomes.
  • The results on improving operational indicators from deploying Adoreboard have been both impressive and impactful to the business and frontline clinical staff."

HEALTHSCOPE : AI ENABLES PATIENT EMOTIONS TO BE ANALYSED IMPROVING HOSPITAL EXPERIENCE.

Retrieved on: 
Sunday, October 15, 2023
Food, Perception, Hospital, ICC, Emotion, AI, Anger, Queen's University, Heart, Procter & Gamble, University, Artificial intelligence, Trust, Experience, Rock and Blues Custom Show, Patient, Allstate, Comment, Nursing, Medical device, Retail, Amazon, Outcome, Healthscope

Anita Hodge National Manager Reported Experience and Outcomes for Healthscope says going beyond numbers to "understand patient emotions and each individual story" now plays a key role to better understanding how to improve patient experience.

Key Points: 
  • Anita Hodge National Manager Reported Experience and Outcomes for Healthscope says going beyond numbers to "understand patient emotions and each individual story" now plays a key role to better understanding how to improve patient experience.
  • Patient experience includes everything from admissions processes, to the food patients eat, to the bedside manner of clinicians to patients being discharged.
  • By improving factors such as these, evidence from clinical studies have shown this leads to better patient outcomes.
  • The results on improving operational indicators from deploying Adoreboard have been both impressive and impactful to the business and frontline clinical staff."

New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

Retrieved on: 
Wednesday, October 11, 2023
Incidence, Health, COVID-19, Public, ASX, CSL, Outcome, Death, Season, Influenza, Vaccination, Person, Immunization, ICU, Vaccine

The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass.

Key Points: 
  • The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass.
  • from October 11-15, 2023.
  • "Observing an ever-growing set of real-world outcomes is critical to ensuring that cell-based influenza vaccine technology continues to push public health forward."
  • "With the 2023/24 Northern Hemisphere influenza season underway, we're committed to working with our partners in public health to help demonstrate the importance of vaccination for our communities and health systems, particularly following a significant drop in flu immunization rates since the COVID-19 pandemic."